An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus
Open Access
- 16 February 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 3 (4), 303-307
- https://doi.org/10.1021/ml2002955
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Towards the design of combination therapy for the treatment of enterovirus infectionsAntiviral Research, 2011
- The ABCs of Rhinoviruses, Wheezing, and AsthmaJournal of Virology, 2010
- Rhinovirus chemotherapyAntiviral Research, 2006
- Relationship of Pleconaril Susceptibility and Clinical Outcomes in Treatment of Common Colds Caused by RhinovirusesAntimicrobial Agents and Chemotherapy, 2005
- In Vitro Antiviral Activity and Single-Dose Pharmacokinetics in Humans of a Novel, Orally Bioavailable Inhibitor of Human Rhinovirus 3C ProteaseAntimicrobial Agents and Chemotherapy, 2005
- 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binderBioorganic & Medicinal Chemistry Letters, 2005
- In Vitro Activity of Expanded-Spectrum Pyridazinyl Oxime Ethers Related to Pirodavir: Novel Capsid-Binding Inhibitors with Potent Antipicornavirus ActivityAntimicrobial Agents and Chemotherapy, 2004
- An Orally Bioavailable Oxime Ether Capsid Binder with Potent Activity against Human RhinovirusJournal of Medicinal Chemistry, 2003
- Pharmacokinetics and Safety of an Antirhinoviral Agent, Ruprintrivir, in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2002
- The structure of antiviral agents that inhibit uncoating when complexed with viral capsidesAntiviral Research, 1989